NOAEL Studies
Cosmetic Ingredient
PABA NOAEL Studies
CAS: 150-13-0
Raw No Observed Adverse Effect Level endpoint records grouped by source. This page does not render calculated Margin of Safety values.
IARC Monographs 3 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| IARC Monographs | IARC carcinogenicity classification | 3 | IARC group | - | - | 1987 | IARC Monographs | {"additional_info":"volume_publication_year=1987","evaluation_year":1987,"source_table":"iarc_classifications","volume":"16, Sup 7"} |
| IARC Monographs | IARC carcinogenicity classification | 3 | IARC group | - | - | 1987 | IARC Monographs | {"additional_info":"volume_publication_year=1987","evaluation_year":1987,"source_table":"iarc_classifications","volume":"16, Sup 7"} |
| IARC Monographs | IARC carcinogenicity classification | 3 | IARC group | - | - | 1987 | IARC Monographs | {"additional_info":"volume_publication_year=1987","evaluation_year":1987,"source_table":"iarc_classifications","volume":"16, Sup 7"} |
NTP_ICE_adme_parameters 2 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| NTP_ICE_adme_parameters | Clint | 0 | uL/min/10^6 cells | Human | - | - | Measured; httk, Human Hepatic Intrinsic Clearance | sheet=Data; excel_row=2504; Record_ID=adme_parameters_865; Data_Type=Measured; DTXSID=DTXSID6024466; Assay=httk, Human Hepatic Intrinsic Clearance; Endpoint=Clint; Response=0.0; Response_Unit=ul/min/10^6 cells; Species=Human; Reference=httk2.3.1, Wambaugh 2019; URL=https://cran.r-project.org/web/packages/httk/index.html; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_adme_parameters | Fu | 0.766 | fraction | Human | - | - | Measured; httk, Human Plasma Fraction Unbound | sheet=Data; excel_row=2503; Record_ID=adme_parameters_865; Data_Type=Measured; DTXSID=DTXSID6024466; Assay=httk, Human Plasma Fraction Unbound; Endpoint=Fu; Response=0.766; Response_Unit=Unitless Fraction; Species=Human; Reference=httk2.3.1, Wambaugh 2019; URL=https://cran.r-project.org/web/packages/httk/index.html; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
NTP_ICE_cancer 1 endpoint
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| NTP_ICE_cancer | IARC group | 3 | unitless | - | - | - | WOE; IARC Carcinogenicity | sheet=Data; excel_row=6967; Record_ID=cancer_7072; Data_Type=WOE; Formulation_Name=4-Aminobenzoic acid; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=IARC Carcinogenicity; Endpoint=IARC group; Response=3; Response_Unit=Unitless; URL=http://publications.iarc.fr/34; http://publications.iarc.fr/139; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
NTP_ICE_endocrine 1 endpoint
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| NTP_ICE_endocrine | Model Score | 0 | unitless | - | - | - | ARPathway2016; AR Pathway Model, Antagonist | sheet=Integrated_approaches; excel_row=3608; RecordID=ARPathway2016_879; DatasetName=ARPathway2016; DTXSID=DTXSID6024466; Assay=AR Pathway Model, Antagonist; Endpoint=Model Score; Response=0; Response_Unit=Unitless; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
NTP_ICE_skin_sensitization 33 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| NTP_ICE_skin_sensitization | CD86, EC150 | >200 | ug/mL | - | Dermal | - | In Vitro; CE_USENSE2018; U-SENS | sheet=Data_invitro; excel_row=8646; Record_ID=skin_sensitization_invitro_2392; Data_Type=In Vitro; Internal_Data_Source=CE_USENSE2018; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=U-SENS; Endpoint=CD86, EC150; Response_Modifier=>; Reported_Response_Modifier=>; Reported_Response=200; Reported_Response_Unit=ug/mL; Response=200; Response_Unit=ug/mL; Reference=Piroird et al. 2015; 25820135; 10.1016/j.tiv.2015.03.009; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | CV75 | >1000 | ug/mL | - | Dermal | - | In Vitro; CE_hCLAT2018; h-CLAT | sheet=Data_invitro; excel_row=2290; Record_ID=skin_sensitization_invitro_561; Data_Type=In Vitro; Internal_Data_Source=CE_hCLAT2018; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=h-CLAT; Endpoint=CV75; Response_Modifier=>; Reported_Response_Modifier=>; Reported_Response=1000; Reported_Response_Unit=ug/mL; Response=1000; Response_Unit=ug/mL; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Cys | 1 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5594; Record_ID=skin_sensitization_invitro_1312; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Cys; Reported_Response=1; Reported_Response_Unit=%; Response=1; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Cys | 1.4 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5552; Record_ID=skin_sensitization_invitro_1302; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Cys; Reported_Response=1.4; Reported_Response_Unit=%; Response=1.4; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Cys | 3.9 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5529; Record_ID=skin_sensitization_invitro_1296; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Cys; Reported_Response=3.9; Reported_Response_Unit=%; Response=3.9; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Cys | 4.6 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5543; Record_ID=skin_sensitization_invitro_1300; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Cys; Reported_Response=4.5999999999999996; Reported_Response_Unit=%; Response=4.6; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Cys | 5.9 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5515; Record_ID=skin_sensitization_invitro_1294; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Cys; Reported_Response=5.9; Reported_Response_Unit=%; Response=5.9; Response_Unit=%; Reference=Bauch et al. 2012; 22659254; 10.1016/j.yrtph.2012.05.013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Cys | 10.6 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5535; Record_ID=skin_sensitization_invitro_1298; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Cys; Reported_Response=10.6; Reported_Response_Unit=%; Response=10.6; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Cys | 10.7 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5525; Record_ID=skin_sensitization_invitro_1295; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Cys; Reported_Response=10.7; Reported_Response_Unit=%; Response=10.7; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys | 0 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5558; Record_ID=skin_sensitization_invitro_1304; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys; Reported_Response=0; Reported_Response_Unit=%; Response=0; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys | 0.1 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5541; Record_ID=skin_sensitization_invitro_1300; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys; Reported_Response=0.1; Reported_Response_Unit=%; Response=0.1; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys | 0.4 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5522; Record_ID=skin_sensitization_invitro_1295; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys; Reported_Response=0.4; Reported_Response_Unit=%; Response=0.4; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys | 0.5 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5513; Record_ID=skin_sensitization_invitro_1294; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys; Reported_Response=0.5; Reported_Response_Unit=%; Response=0.5; Response_Unit=%; Reference=Bauch et al. 2012; 22659254; 10.1016/j.yrtph.2012.05.013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys | 0.6 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5533; Record_ID=skin_sensitization_invitro_1298; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys; Reported_Response=0.6; Reported_Response_Unit=%; Response=0.6; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys | 0.7 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5550; Record_ID=skin_sensitization_invitro_1302; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys; Reported_Response=0.7; Reported_Response_Unit=%; Response=0.7; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys | 0.9 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5528; Record_ID=skin_sensitization_invitro_1296; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys; Reported_Response=0.9; Reported_Response_Unit=%; Response=0.9; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys + Cys | 0.35 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5588; Record_ID=skin_sensitization_invitro_1310; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys + Cys; Reported_Response=0.35; Reported_Response_Unit=%; Response=0.35; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys + Cys | 0.45 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5562; Record_ID=skin_sensitization_invitro_1304; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys + Cys; Reported_Response=0.45; Reported_Response_Unit=%; Response=0.45; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys + Cys | 1.05 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5554; Record_ID=skin_sensitization_invitro_1302; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys + Cys; Reported_Response=1.05; Reported_Response_Unit=%; Response=1.05; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys + Cys | 2.3 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5570; Record_ID=skin_sensitization_invitro_1306; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys + Cys; Reported_Response=2.2999999999999998; Reported_Response_Unit=%; Response=2.3; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys + Cys | 2.35 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5546; Record_ID=skin_sensitization_invitro_1300; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys + Cys; Reported_Response=2.35; Reported_Response_Unit=%; Response=2.35; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys + Cys | 2.4 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5530; Record_ID=skin_sensitization_invitro_1296; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys + Cys; Reported_Response=2.4; Reported_Response_Unit=%; Response=2.4; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys + Cys | 3.2 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5518; Record_ID=skin_sensitization_invitro_1294; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys + Cys; Reported_Response=3.2; Reported_Response_Unit=%; Response=3.2; Response_Unit=%; Reference=Bauch et al. 2012; 22659254; 10.1016/j.yrtph.2012.05.013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys + Cys | 5.55 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5526; Record_ID=skin_sensitization_invitro_1295; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys + Cys; Reported_Response=5.55; Reported_Response_Unit=%; Response=5.55; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Depletion Lys + Cys | 5.6 | % | - | Dermal | - | In Vitro; DPRA2015; DPRA | sheet=Data_invitro; excel_row=5537; Record_ID=skin_sensitization_invitro_1298; Data_Type=In Vitro; Internal_Data_Source=DPRA2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=DPRA; Endpoint=Depletion Lys + Cys; Reported_Response=5.6; Reported_Response_Unit=%; Response=5.6; Response_Unit=%; Reference=Joint Research Centre of the European Union 2013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | EC1.5 | >2000 | uM | - | Dermal | - | In Vitro; CE_KeratinoSense2018; KeratinoSens | sheet=Data_invitro; excel_row=5228; Record_ID=skin_sensitization_invitro_1221; Data_Type=In Vitro; Internal_Data_Source=CE_KeratinoSense2018; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=KeratinoSens; Endpoint=EC1.5; Response_Modifier=>; Reported_Response_Modifier=>; Reported_Response=2000; Reported_Response_Unit=uM; Response=2000; Response_Unit=uM; Reference=Natsch et al. 2013; 23576290; 10.1002/jat.2868|Joint Research Centre of the European Union 2014|Urbisch et al. 2015; 25541156; 10.1016/j.yrtph.2014.12.008; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | IC50 | >2400 | uM | - | Dermal | - | In Vitro; Urbisch_SkinSensitization2020; LuSens | sheet=Data_invitro; excel_row=7642; Record_ID=skin_sensitization_invitro_1810; Data_Type=In Vitro; Internal_Data_Source=Urbisch_SkinSensitization2020; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=LuSens; Endpoint=IC50; Response_Modifier=>; Reported_Response_Modifier=>; Reported_Response=2400; Reported_Response_Unit=uM; Response=2400; Response_Unit=uM; Reference=Urbisch et al. 2015; 25541156; 10.1016/j.yrtph.2014.12.008; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Imax | 1.107 | ratio | - | Dermal | - | In Vitro; Urbisch_SkinSensitization2020; LuSens | sheet=Data_invitro; excel_row=7544; Record_ID=skin_sensitization_invitro_1810; Data_Type=In Vitro; Internal_Data_Source=Urbisch_SkinSensitization2020; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=LuSens; Endpoint=Imax; Reported_Response=1.106609205; Reported_Response_Unit=Unitless; Response=1.107; Response_Unit=Ratio; Reference=Urbisch et al. 2015; 25541156; 10.1016/j.yrtph.2014.12.008; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Imax | 1.21 | ratio | - | Dermal | - | In Vitro; CE_KeratinoSense2018; KeratinoSens | sheet=Data_invitro; excel_row=5233; Record_ID=skin_sensitization_invitro_1221; Data_Type=In Vitro; Internal_Data_Source=CE_KeratinoSense2018; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=KeratinoSens; Endpoint=Imax; Reported_Response=1.21; Reported_Response_Unit=Unitless; Response=1.21; Response_Unit=Ratio; Reference=Natsch et al. 2013; 23576290; 10.1002/jat.2868|Joint Research Centre of the European Union 2014|Urbisch et al. 2015; 25541156; 10.1016/j.yrtph.2014.12.008; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Imax | 1.23 | ratio | - | Dermal | - | In Vitro; KeratinoSens2015; KeratinoSens | sheet=Data_invitro; excel_row=5234; Record_ID=skin_sensitization_invitro_1222; Data_Type=In Vitro; Internal_Data_Source=KeratinoSens2015; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=KeratinoSens; Endpoint=Imax; Reported_Response=1.23; Reported_Response_Unit=Unitless; Response=1.23; Response_Unit=Ratio; Reference=Bauch et al. 2012; 22659254; 10.1016/j.yrtph.2012.05.013; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Incidence of positive responses | 0 | % | Human | Dermal | - | In Vivo; HPPT2020WIP; Human Maximization Test | sheet=Data_invivo; excel_row=5607; Record_ID=skin_sensitization_invivo_1297; Data_Type=In Vivo; Internal_Data_Source=HPPT2020WIP; Concentration=25.0; Concentration_Units=%; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=Human Maximization Test; Endpoint=Incidence of positive responses; Response=0; Response_Unit=%; Species=Human; Route=Dermal; Reference=Kligman 1966; 5924294; 10.1038/jid.1966.160|Basketter et al. 1994; 8045461; 10.1016/0278-6915(94)90112-0|Basketter et al. 1999; 10654593; 10.1016/S0278-6915(99)00112-x|Gerberick et al. 2000; 10684384; 10.1053/ajcd.2000.0003|Schneider and Akkan 2004; 15135206; 10.1016/j.yrtph.2004.02.002; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Induction dose per skin area | 15520 | ug/cm2 | Human | Dermal | - | In Vivo; HPPT2020WIP; Human Maximization Test | sheet=Data_invivo; excel_row=5605; Record_ID=skin_sensitization_invivo_1297; Data_Type=In Vivo; Internal_Data_Source=HPPT2020WIP; Concentration=25.0; Concentration_Units=%; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=Human Maximization Test; Endpoint=Induction dose per skin area; Response=15520; Response_Unit=ug/cm2; Species=Human; Route=Dermal; Reference=Kligman 1966; 5924294; 10.1038/jid.1966.160|Basketter et al. 1994; 8045461; 10.1016/0278-6915(94)90112-0|Basketter et al. 1999; 10654593; 10.1016/S0278-6915(99)00112-x|Gerberick et al. 2000; 10684384; 10.1053/ajcd.2000.0003|Schneider and Akkan 2004; 15135206; 10.1016/j.yrtph.2004.02.002; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
| NTP_ICE_skin_sensitization | Relative reliability score | 1 | unitless | Human | Dermal | - | In Vivo; HPPT2020WIP; Human Maximization Test | sheet=Data_invivo; excel_row=5610; Record_ID=skin_sensitization_invivo_1297; Data_Type=In Vivo; Internal_Data_Source=HPPT2020WIP; Concentration=25.0; Concentration_Units=%; Mixture=Chemical; DTXSID=DTXSID6024466; Assay=Human Maximization Test; Endpoint=Relative reliability score; Response=1; Response_Unit=Unitless; Species=Human; Route=Dermal; Reference=Kligman 1966; 5924294; 10.1038/jid.1966.160|Basketter et al. 1994; 8045461; 10.1016/0278-6915(94)90112-0|Basketter et al. 1999; 10654593; 10.1016/S0278-6915(99)00112-x|Gerberick et al. 2000; 10684384; 10.1053/ajcd.2000.0003|Schneider and Akkan 2004; 15135206; 10.1016/j.yrtph.2004.02.002; URL_CompTox=https://comptox.epa.gov/dashboard/chemical/details/DTXSID6024466; URL_CEBS=https://doi.org/10.22427/NTP-DATA-DTXSID6024466 |
SCCS_vision_codex 16 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| SCCS_vision_codex | NOAEL | =0.1 | % | rat | oral | 51-year | NOAEL study | {"citation":"Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0","dose":"1 mg x 32.0/0.320 = 100 mg/kg/d).","effect":"showed that PABA might accumulate in tissues and blood, but only to a relatively limited extent. Plasma aspartate aminotransferase activities in rats given 0.5% and 1% PABA were significantly lower (p<0.05) than that of control rats at week 2, but not at week 1 or 4. 1% PABA in the drinking water, significantly decreased t- butylhydroperoxide-induced lipid peroxidation in the liver (p<0.05) but not in the kidney. Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0.1% PABA in drinking water (According to Sprague Dawley – Ace Animals, Inc http://WWW.aceanimals.com) daily intake 10 – 12 ml/100 g bw/d. From the paper, the body weight at the end of the experiment was 320 g. This would correspond to a water intake of 10 x 3.2 = 32.0 ml, weight 320 g; 1 mg x 32.0/0.320 = 100 mg/kg/d). Humans A case report regarding a 51-year-old man admitted to the hospital with a seven-day history of progressive myalgias, generalized weakness and fever. The man had been trea","page":17,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_002"} |
| SCCS_vision_codex | NOAEL | =0.1 | % | rat | oral | 51-year | NOAEL study | {"citation":"Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0","dose":"1 mg x 32.0/0.320 = 100 mg/kg/d).","effect":"showed that PABA might accumulate in tissues and blood, but only to a relatively limited extent. Plasma aspartate aminotransferase activities in rats given 0.5% and 1% PABA were significantly lower (p<0.05) than that of control rats at week 2, but not at week 1 or 4. 1% PABA in the drinking water, significantly decreased t- butylhydroperoxide-induced lipid peroxidation in the liver (p<0.05) but not in the kidney. Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0.1% PABA in drinking water (According to Sprague Dawley – Ace Animals, Inc http://WWW.aceanimals.com) daily intake 10 – 12 ml/100 g bw/d. From the paper, the body weight at the end of the experiment was 320 g. This would correspond to a water intake of 10 x 3.2 = 32.0 ml, weight 320 g; 1 mg x 32.0/0.320 = 100 mg/kg/d). Humans A case report regarding a 51-year-old man admitted to the hospital with a seven-day history of progressive myalgias, generalized weakness and fever. The man had been trea","page":17,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_002"} |
| SCCS_vision_codex | NOAEL | =0.1 | % | rat | oral | 51-year | NOAEL study | {"citation":"Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0","dose":"1 mg x 32.0/0.320 = 100 mg/kg/d).","effect":"showed that PABA might accumulate in tissues and blood, but only to a relatively limited extent. Plasma aspartate aminotransferase activities in rats given 0.5% and 1% PABA were significantly lower (p<0.05) than that of control rats at week 2, but not at week 1 or 4. 1% PABA in the drinking water, significantly decreased t- butylhydroperoxide-induced lipid peroxidation in the liver (p<0.05) but not in the kidney. Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0.1% PABA in drinking water (According to Sprague Dawley – Ace Animals, Inc http://WWW.aceanimals.com) daily intake 10 – 12 ml/100 g bw/d. From the paper, the body weight at the end of the experiment was 320 g. This would correspond to a water intake of 10 x 3.2 = 32.0 ml, weight 320 g; 1 mg x 32.0/0.320 = 100 mg/kg/d). Humans A case report regarding a 51-year-old man admitted to the hospital with a seven-day history of progressive myalgias, generalized weakness and fever. The man had been trea","page":17,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_002"} |
| SCCS_vision_codex | NOAEL | =0.1 | % | rat | oral | 51-year | NOAEL study | {"citation":"Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0","dose":"1 mg x 32.0/0.320 = 100 mg/kg/d).","effect":"showed that PABA might accumulate in tissues and blood, but only to a relatively limited extent. Plasma aspartate aminotransferase activities in rats given 0.5% and 1% PABA were significantly lower (p<0.05) than that of control rats at week 2, but not at week 1 or 4. 1% PABA in the drinking water, significantly decreased t- butylhydroperoxide-induced lipid peroxidation in the liver (p<0.05) but not in the kidney. Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0.1% PABA in drinking water (According to Sprague Dawley – Ace Animals, Inc http://WWW.aceanimals.com) daily intake 10 – 12 ml/100 g bw/d. From the paper, the body weight at the end of the experiment was 320 g. This would correspond to a water intake of 10 x 3.2 = 32.0 ml, weight 320 g; 1 mg x 32.0/0.320 = 100 mg/kg/d). Humans A case report regarding a 51-year-old man admitted to the hospital with a seven-day history of progressive myalgias, generalized weakness and fever. The man had been trea","page":17,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_002"} |
| SCCS_vision_codex | NOAEL | =1 | % | rat | oral | 5 weeks | NOAEL study | {"citation":"Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals","dose":"SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month.","effect":"SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month. All rats survived and the gain in body weight for all 3 groups was the same. The autopsies on all of the animals were negative. NOAEL is larger than 1.4 g/kg body weight. Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals (sex not given) (5 weeks old at start of study, weight 150 g) Test substance: PABA as potassium salt (High grade, Sigma Chemical Co., St. Louis, MO, USA) Batch: / Purity: / Dose levels: 0, 0.1, 0.5, and 1% PABA in deionised water Route: Oral, in drinking water Exposure period: 4 week Experime","page":17,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_001"} |
| SCCS_vision_codex | NOAEL | =1 | % | rat | oral | 5 weeks | NOAEL study | {"citation":"Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals","dose":"SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month.","effect":"SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month. All rats survived and the gain in body weight for all 3 groups was the same. The autopsies on all of the animals were negative. NOAEL is larger than 1.4 g/kg body weight. Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals (sex not given) (5 weeks old at start of study, weight 150 g) Test substance: PABA as potassium salt (High grade, Sigma Chemical Co., St. Louis, MO, USA) Batch: / Purity: / Dose levels: 0, 0.1, 0.5, and 1% PABA in deionised water Route: Oral, in drinking water Exposure period: 4 week Experime","page":17,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_001"} |
| SCCS_vision_codex | NOAEL | =1 | % | rat | oral | 5 weeks | NOAEL study | {"citation":"Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals","dose":"SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month.","effect":"SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month. All rats survived and the gain in body weight for all 3 groups was the same. The autopsies on all of the animals were negative. NOAEL is larger than 1.4 g/kg body weight. Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals (sex not given) (5 weeks old at start of study, weight 150 g) Test substance: PABA as potassium salt (High grade, Sigma Chemical Co., St. Louis, MO, USA) Batch: / Purity: / Dose levels: 0, 0.1, 0.5, and 1% PABA in deionised water Route: Oral, in drinking water Exposure period: 4 week Experime","page":17,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_001"} |
| SCCS_vision_codex | NOAEL | =1 | % | rat | oral | 5 weeks | NOAEL study | {"citation":"Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals","dose":"SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month.","effect":"SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month. All rats survived and the gain in body weight for all 3 groups was the same. The autopsies on all of the animals were negative. NOAEL is larger than 1.4 g/kg body weight. Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals (sex not given) (5 weeks old at start of study, weight 150 g) Test substance: PABA as potassium salt (High grade, Sigma Chemical Co., St. Louis, MO, USA) Batch: / Purity: / Dose levels: 0, 0.1, 0.5, and 1% PABA in deionised water Route: Oral, in drinking water Exposure period: 4 week Experime","page":17,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_001"} |
| SCCS_vision_codex | NOAEL | =100 | mg/kg bw/d | rat | oral | 2 weeks | repeated dose toxicity | {"dose":"Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d.","effect":"g or preventing the radiation from reaching the vulnerable, living skin tissue. 3.3.13. Safety evaluation (including calculation of the MoS) CALCULATION OF THE MARGIN OF SAFETY Not applicable 3.3.14. Discussion The safety has only been considered for dermal exposure PABA has low acute oral toxicity, more than 2 g/kg bw in rodents. Applications of 5% PABA in sunscreen formulation on human skin have shown that irritation is negligible. Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d. In two patients who were administered PABA orally for about four weeks (12 g/day) signs of hepatic injury were observed (LOAEL = 200 mg/kg bw/d). PABA did not induce mutations in bacteria, but induced an increased incidence of chromosome damage to CHO cells. PABA did not induce tumours in a skin painting study with Swiss mice. PABA has been tested for reproductive toxicity in rats and Drosophila melan","page":47,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_005"} |
| SCCS_vision_codex | NOAEL | =100 | mg/kg bw/d | rat | oral | 2 weeks | repeated dose toxicity | {"dose":"Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d.","effect":"g or preventing the radiation from reaching the vulnerable, living skin tissue. 3.3.13. Safety evaluation (including calculation of the MoS) CALCULATION OF THE MARGIN OF SAFETY Not applicable 3.3.14. Discussion The safety has only been considered for dermal exposure PABA has low acute oral toxicity, more than 2 g/kg bw in rodents. Applications of 5% PABA in sunscreen formulation on human skin have shown that irritation is negligible. Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d. In two patients who were administered PABA orally for about four weeks (12 g/day) signs of hepatic injury were observed (LOAEL = 200 mg/kg bw/d). PABA did not induce mutations in bacteria, but induced an increased incidence of chromosome damage to CHO cells. PABA did not induce tumours in a skin painting study with Swiss mice. PABA has been tested for reproductive toxicity in rats and Drosophila melan","page":47,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_005"} |
| SCCS_vision_codex | NOAEL | =100 | mg/kg bw/d | rat | oral | 2 weeks | repeated dose toxicity | {"dose":"Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d.","effect":"g or preventing the radiation from reaching the vulnerable, living skin tissue. 3.3.13. Safety evaluation (including calculation of the MoS) CALCULATION OF THE MARGIN OF SAFETY Not applicable 3.3.14. Discussion The safety has only been considered for dermal exposure PABA has low acute oral toxicity, more than 2 g/kg bw in rodents. Applications of 5% PABA in sunscreen formulation on human skin have shown that irritation is negligible. Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d. In two patients who were administered PABA orally for about four weeks (12 g/day) signs of hepatic injury were observed (LOAEL = 200 mg/kg bw/d). PABA did not induce mutations in bacteria, but induced an increased incidence of chromosome damage to CHO cells. PABA did not induce tumours in a skin painting study with Swiss mice. PABA has been tested for reproductive toxicity in rats and Drosophila melan","page":47,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_005"} |
| SCCS_vision_codex | NOAEL | =100 | mg/kg bw/d | rat | oral | 2 weeks | repeated dose toxicity | {"dose":"Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d.","effect":"g or preventing the radiation from reaching the vulnerable, living skin tissue. 3.3.13. Safety evaluation (including calculation of the MoS) CALCULATION OF THE MARGIN OF SAFETY Not applicable 3.3.14. Discussion The safety has only been considered for dermal exposure PABA has low acute oral toxicity, more than 2 g/kg bw in rodents. Applications of 5% PABA in sunscreen formulation on human skin have shown that irritation is negligible. Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d. In two patients who were administered PABA orally for about four weeks (12 g/day) signs of hepatic injury were observed (LOAEL = 200 mg/kg bw/d). PABA did not induce mutations in bacteria, but induced an increased incidence of chromosome damage to CHO cells. PABA did not induce tumours in a skin painting study with Swiss mice. PABA has been tested for reproductive toxicity in rats and Drosophila melan","page":47,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_005"} |
| SCCS_vision_codex | NOAEL | =108 | - | - | oral | 108 days | NOAEL study | {"citation":"Ref.: 29","dose":"No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA.","effect":"ography. Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29","page":18,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_003"} |
| SCCS_vision_codex | NOAEL | =108 | - | - | oral | 108 days | NOAEL study | {"citation":"Ref.: 29","dose":"No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA.","effect":"ography. Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29","page":18,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_003"} |
| SCCS_vision_codex | NOAEL | =108 | - | - | oral | 108 days | NOAEL study | {"citation":"Ref.: 29","dose":"No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA.","effect":"ography. Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29","page":18,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_003"} |
| SCCS_vision_codex | NOAEL | =108 | - | - | oral | 108 days | NOAEL study | {"citation":"Ref.: 29","dose":"No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA.","effect":"ography. Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29","page":18,"pdf":"sccp_o_058.pdf","row_type":"noael_study","study_id":"sccp_o_058_noael_003"} |
ToxValDB_ECHA_IUCLID 1 endpoint
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| ToxValDB_ECHA_IUCLID | NOAEL | >=1200 | mg/kg bw/day | Rat | oral | chronic; 108 days | chronic | QUALITY=2 (reliable with restrictions); STORED_SOURCE_RECORD=https://clowder.edap-cluster.com/files/669ead7de4b0a7c65d1c470c; RECORD_SOURCE_LEVEL=Extraction document; SOURCE_URL=https://echa.europa.eu/; SUBSOURCE_URL=https://echa.europa.eu/registration-dossier/-/registered-dossier/7095/7/6/2?documentUUID=2ff1de7d-7a75-41c5-89d9-7e3a25652645; YEAR=2016; ORIGINAL_YEAR=2016; STUDY_GROUP=ECHA IUCLID:15839933:F:--; QC_CATEGORY=Programmatically extracted from structured data source; Source overall passed QC, but this record was not manually checked; QC_STATUS=not determined; SOURCE_HASH=ToxValhc_5e3ce39d9a151e738e14a6ee5f2eeb6b |
ToxValDB_GESTIS_DNEL 1 endpoint
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| ToxValDB_GESTIS_DNEL | DNEL systemic | =10.58 | mg/m3 | Human | inhalation | - | Toxicity Value | STORED_SOURCE_RECORD=https://clowder.edap-cluster.com/files/6543dd69e4b045b9ff7cd87e; RECORD_SOURCE_LEVEL=Extraction document; SOURCE_URL=https://www.dguv.de/ifa/gestis/gestis-dnel-liste/index-2.jsp; STUDY_GROUP=GESTIS DNEL:15629717:-:--; QC_CATEGORY=Programmatically extracted from structured data source; Source overall passed QC, but this record was not manually checked; QC_STATUS=not determined; SOURCE_HASH=ToxValhc_81b47b85fefc7ed055987bd887f58c47 |
UnifiedCodex:SCCS_SHADOW:beta.noael_studies 5 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| UnifiedCodex:SCCS_SHADOW:beta.noael_studies | - | 0.1 | % | rat | oral | 51-year | - | SOURCE_SUBDIR=sccp_o_058; REPORT_TITLE=Opinion on 4-Aminobenzoic acid (PABA) COLIPA n° S1; OPINION_NUMBER=SCCP/1008/06; COMMITTEE=SCCP; REPORT_DATE=20 June 2006; VALUE_TEXT=0.1; DOSE=1 mg x 32.0/0.320 = 100 mg/kg/d).; EFFECT=showed that PABA might accumulate in tissues and blood, but only to a relatively limited extent. Plasma aspartate aminotransferase activities in rats given 0.5% and 1% PABA were significantly lower (p<0.05) than that of control rats at week 2, but not at week 1 or 4. 1% PABA in the drinking water, significantly decreased t- butylhydroperoxide-induced lipid peroxidation in the liver (p<0.05) but not in the kidney. Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0.1% PABA in drinking water (According to Sprague Dawley – Ace Animals, Inc http://WWW.aceanimals.com) daily intake 10 – 12 ml/100 g bw/d. From the paper, the body weight at the end of the experiment was 320 g. This would correspond to a water intake of 10 x 3.2 = 32.0 ml, weight 320 g; 1 mg x 32.0/0.320 = 100 mg/kg/d). Humans A case report regarding a 51-year-old man admitted to the hospital with a seven-day history of progressive myalgias, generalized weakness and fever. The man had been trea; CITATION=Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0; CITATION_NUMBERS=[26]; REFERENCE=Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0; DETAILS_JSON={"cas_number":"150-13-0","citation":"Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0","dose":"1 mg x 32.0/0.320 = 100 mg/kg/d).","duration":"51-year","effect":"showed that PABA might accumulate in tissues and blood, but only to a relatively limited extent. Plasma aspartate aminotransferase activities in rats given 0.5% and 1% PABA were significantly lower (p<0.05) than that of control rats at week 2, but not at week 1 or 4. 1% PABA in the drinking water, significantly decreased t- butylhydroperoxide-induced lipid peroxidation in the liver (p<0.05) but not in the kidney. Ref.: 26 Comment Based on the effect on the effect on plasma aspartate aminotransferase activities, a NOEL could be equal to 0.1% PABA in drinking water (According to Sprague Dawley – Ace Animals, Inc http://WWW.aceanimals.com) daily intake 10 – 12 ml/100 g bw/d. From the paper, the body weight at the end of the experiment was 320 g. This would correspond to a water intake of 10 x 3.2 = 32.0 ml, weight 320 g; 1 mg x 32.0/0.320 = 100 mg/kg/d). Humans A case report regarding a 51-year-old man admitted to the hospital with a seven-day history of progressive myalgias, generalized weakness and fever. The man had been trea","endpoint":"","ingredient":"Primary name","loael_value":"","noael_unit":"%","noael_value":"0.1","page":17,"route":"oral","species":"rat","study_id":"sccp_o_058_noael_002"} |
| UnifiedCodex:SCCS_SHADOW:beta.noael_studies | - | 1 | % | rat | oral | 5 weeks | - | SOURCE_SUBDIR=sccp_o_058; REPORT_TITLE=Opinion on 4-Aminobenzoic acid (PABA) COLIPA n° S1; OPINION_NUMBER=SCCP/1008/06; COMMITTEE=SCCP; REPORT_DATE=20 June 2006; VALUE_TEXT=1; DOSE=SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month.; EFFECT=SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month. All rats survived and the gain in body weight for all 3 groups was the same. The autopsies on all of the animals were negative. NOAEL is larger than 1.4 g/kg body weight. Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals (sex not given) (5 weeks old at start of study, weight 150 g) Test substance: PABA as potassium salt (High grade, Sigma Chemical Co., St. Louis, MO, USA) Batch: / Purity: / Dose levels: 0, 0.1, 0.5, and 1% PABA in deionised water Route: Oral, in drinking water Exposure period: 4 week Experime; CITATION=Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals; CITATION_NUMBERS=[13,12]; REFERENCE=Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals; DETAILS_JSON={"cas_number":"150-13-0","citation":"Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals","dose":"SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month.","duration":"5 weeks","effect":"SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 17 Rats are resistant to oral administered PABA and tolerate 1.4 g/kg bw for about a month. All rats survived and the gain in body weight for all 3 groups was the same. The autopsies on all of the animals were negative. NOAEL is larger than 1.4 g/kg body weight. Ref.: 13 Determination of accumulation of PABA in blood, liver, and kidney and the overt toxicity of PABA in rats Guideline: / Species/strain: Sprague-Dawley rats Group size: 12 animals (sex not given) (5 weeks old at start of study, weight 150 g) Test substance: PABA as potassium salt (High grade, Sigma Chemical Co., St. Louis, MO, USA) Batch: / Purity: / Dose levels: 0, 0.1, 0.5, and 1% PABA in deionised water Route: Oral, in drinking water Exposure period: 4 week Experime","endpoint":"","ingredient":"Primary name","loael_value":"","noael_unit":"%","noael_value":"1","page":17,"route":"oral","species":"rat","study_id":"sccp_o_058_noael_001"} |
| UnifiedCodex:SCCS_SHADOW:beta.noael_studies | - | 108 | - | - | oral | 108 days | - | SOURCE_SUBDIR=sccp_o_058; REPORT_TITLE=Opinion on 4-Aminobenzoic acid (PABA) COLIPA n° S1; OPINION_NUMBER=SCCP/1008/06; COMMITTEE=SCCP; REPORT_DATE=20 June 2006; VALUE_TEXT=unclear:ography. Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29; DOSE=No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA.; EFFECT=ography. Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29; CITATION=Ref.: 29; CITATION_NUMBERS=[29]; REFERENCE=Ref.: 29; DETAILS_JSON={"cas_number":"150-13-0","citation":"Ref.: 29","dose":"No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA.","duration":"108 days","effect":"ography. Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29","endpoint":"","ingredient":"Primary name","loael_value":"","noael_unit":"","noael_value":"unclear:ography. Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29","page":18,"route":"oral","species":"","study_id":"sccp_o_058_noael_003"} |
| UnifiedCodex:SCCS_SHADOW:beta.noael_studies | - | 108 | - | - | oral | 108 days | - | SOURCE_SUBDIR=sccp_o_058; REPORT_TITLE=Opinion on 4-Aminobenzoic acid (PABA) COLIPA n° S1; OPINION_NUMBER=SCCP/1008/06; COMMITTEE=SCCP; REPORT_DATE=20 June 2006; VALUE_TEXT=unclear:Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29; DOSE=No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA.; EFFECT=Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29; CITATION=Ref.: 29; CITATION_NUMBERS=[29]; REFERENCE=Ref.: 29; DETAILS_JSON={"cas_number":"150-13-0","citation":"Ref.: 29","dose":"No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA.","duration":"108 days","effect":"Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29","endpoint":"","ingredient":"Primary name","loael_value":"","noael_unit":"","noael_value":"unclear:Porphyrins were separated by thinlayer chromatography. Neither a simultaneous HCB-PABA (Prophylactic administration) nor PABA application after manifestation of the HCB-porphyria (therapeutic administration) influenced significantly the excretion of urinary porphyrins or precursors. In conclusion, PABA has not shown any effects on the excretion of urinary porphyrins or precursors. No toxic sign were described after 108 days of oral administration of 1.2 g/kg bw of PABA, administered as potassium salt, and NOEL or NOAEL could be stated as equal or larger than 1.2 g/kg bw of PABA. Ref.: 29","page":18,"route":"oral","species":"","study_id":"sccp_o_058_noael_004"} |
| UnifiedCodex:SCCS_SHADOW:beta.noael_studies | repeated dose toxicity | 100 | mg/kg bw/d | rat | oral | 2 weeks | repeated dose toxicity | SOURCE_SUBDIR=sccp_o_058; REPORT_TITLE=Opinion on 4-Aminobenzoic acid (PABA) COLIPA n° S1; OPINION_NUMBER=SCCP/1008/06; COMMITTEE=SCCP; REPORT_DATE=20 June 2006; VALUE_TEXT=100; DOSE=Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d.; LOAEL_VALUE=200 mg/kg bw/d; EFFECT=g or preventing the radiation from reaching the vulnerable, living skin tissue. 3.3.13. Safety evaluation (including calculation of the MoS) CALCULATION OF THE MARGIN OF SAFETY Not applicable 3.3.14. Discussion The safety has only been considered for dermal exposure PABA has low acute oral toxicity, more than 2 g/kg bw in rodents. Applications of 5% PABA in sunscreen formulation on human skin have shown that irritation is negligible. Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d. In two patients who were administered PABA orally for about four weeks (12 g/day) signs of hepatic injury were observed (LOAEL = 200 mg/kg bw/d). PABA did not induce mutations in bacteria, but induced an increased incidence of chromosome damage to CHO cells. PABA did not induce tumours in a skin painting study with Swiss mice. PABA has been tested for reproductive toxicity in rats and Drosophila melan; CITATION_NUMBERS=[]; DETAILS_JSON={"cas_number":"150-13-0","citation":"","dose":"Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d.","duration":"2 weeks","effect":"g or preventing the radiation from reaching the vulnerable, living skin tissue. 3.3.13. Safety evaluation (including calculation of the MoS) CALCULATION OF THE MARGIN OF SAFETY Not applicable 3.3.14. Discussion The safety has only been considered for dermal exposure PABA has low acute oral toxicity, more than 2 g/kg bw in rodents. Applications of 5% PABA in sunscreen formulation on human skin have shown that irritation is negligible. Only few studies have investigated the repeated dose toxicity of PABA, a NOEL based on the transient effect on plasma aspartate aminotransferase activities after 2 weeks was 100 mg/kg bw/d. In two patients who were administered PABA orally for about four weeks (12 g/day) signs of hepatic injury were observed (LOAEL = 200 mg/kg bw/d). PABA did not induce mutations in bacteria, but induced an increased incidence of chromosome damage to CHO cells. PABA did not induce tumours in a skin painting study with Swiss mice. PABA has been tested for reproductive toxicity in rats and Drosophila melan","endpoint":"repeated dose toxicity","ingredient":"Primary name","loael_value":"200 mg/kg bw/d","noael_unit":"mg/kg bw/d","noael_value":"100","page":47,"route":"oral","species":"rat","study_id":"sccp_o_058_noael_005"} |
openFDA substances 4 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| openFDA substances | FDA UNII substance identifier | TL2TJE8QTX | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C7H7NO2","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"TL2TJE8QTX"} |
| openFDA substances | FDA UNII substance identifier | TL2TJE8QTX | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C7H7NO2","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"TL2TJE8QTX"} |
| openFDA substances | FDA UNII substance identifier | TL2TJE8QTX | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C7H7NO2","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"TL2TJE8QTX"} |
| openFDA substances | FDA UNII substance identifier | TL2TJE8QTX | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C7H7NO2","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"TL2TJE8QTX"} |